Holen Sie sich die Stockscreener-App
4.24
0.93%
-0.04
Handel nachbörslich:
4.20
-0.04
-0.94%
Schlusskurs vom Vortag:
$4.28
Offen:
$4.25
24-Stunden-Volumen:
1.18M
Relative Volume:
1.14
Marktkapitalisierung:
$812.80M
Einnahmen:
$12.99M
Nettoeinkommen (Verlust:
$-74.39M
KGV:
-9.6364
EPS:
-0.44
Netto-Cashflow:
$-78.92M
1W Leistung:
-1.17%
1M Leistung:
-4.93%
6M Leistung:
+29.27%
1J Leistung:
+9.84%
1-Tages-Spanne:
$4.10
$4.36
1-Wochen-Bereich:
$4.10
$4.39
52-Wochen-Spanne:
$2.705
$5.10
Arbutus Biopharma Corp Stock (ABUS) Company Profile
Firmenname
Arbutus Biopharma Corp
Sektor
Branche
Telefon
604-419-3200
Adresse
701 VETERANS CIRCLE, WARMINSTER, PA
Vergleichen Sie ABUS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABUS
Arbutus Biopharma Corp
|
4.24 | 787.88M | 12.99M | -74.39M | -78.92M | -0.44 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Arbutus Biopharma Corp Stock (ABUS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-02-02 | Hochstufung | Jefferies | Hold → Buy |
| 2021-02-25 | Eingeleitet | Jefferies | Hold |
| 2020-12-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-07-27 | Fortgesetzt | JMP Securities | Mkt Outperform |
| 2020-07-24 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-05-19 | Hochstufung | Wedbush | Neutral → Outperform |
| 2020-03-06 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2020-02-20 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-02-05 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-10-07 | Bestätigt | B. Riley FBR | Buy |
| 2019-10-04 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2018-10-16 | Hochstufung | B. Riley FBR | Neutral → Buy |
| 2018-10-15 | Hochstufung | Wedbush | Underperform → Neutral |
| 2018-10-12 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-07-06 | Herabstufung | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-03-19 | Fortgesetzt | Chardan Capital Markets | Buy |
| 2018-03-19 | Herabstufung | Wedbush | Outperform → Neutral |
| 2018-01-05 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2017-04-04 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2017-02-01 | Bestätigt | Wedbush | Outperform |
| 2016-12-13 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2016-11-30 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
Alle ansehen
Arbutus Biopharma Corp Aktie (ABUS) Neueste Nachrichten
Can Arbutus Biopharma Corporation stock deliver surprise earnings beatJuly 2025 Review & Risk Controlled Swing Trade Alerts - newser.com
What institutional flow reveals about Arbutus Biopharma CorporationJuly 2025 Momentum & Low Risk Investment Opportunities - newser.com
Arbutus Biopharma to Present New Data on Imdusiran and AB-101 at AASLD 2025 - MyChesCo
Is Arbutus Biopharma Corporation stock a buy on dipsMarket Rally & Safe Entry Trade Reports - newser.com
Arbutus Biopharma (NASDAQ:ABUS) Shares Cross Above 200-Day Moving AverageWhat's Next? - MarketBeat
Risk adjusted return profile for Arbutus Biopharma Corporation analyzedPortfolio Update Report & Growth Oriented Trading Recommendations - newser.com
Arbutus Announces Four Abstracts Accepted for Presentation at AASLDThe Liver Meeting® 2025 - GlobeNewswire
Arbutus Biopharma (ABUS) Showcases Promising Liver Disease Resea - GuruFocus
Has Arbutus Biopharma Corporation formed a bullish divergenceQuarterly Trade Report & Technical Pattern Recognition Alerts - newser.com
Are Medical Stocks Lagging Arbutus Biopharma (ABUS) This Year? - Yahoo Finance
Applying Wyckoff theory to Arbutus Biopharma Corporation stockWeekly Trend Report & Fast Gain Stock Tips - newser.com
Is Arbutus Biopharma Corporation forming a reversal pattern2025 Breakouts & Breakdowns & Verified Momentum Stock Alerts - newser.com
Risk vs reward if holding onto Arbutus Biopharma CorporationRate Cut & Real-Time Volume Analysis - newser.com
Statistical indicators supporting Arbutus Biopharma Corporation’s strengthWeekly Trade Review & Weekly Watchlist for Hot Stocks - newser.com
Voya Investment Management LLC Sells 4,534 Shares of Arbutus Biopharma Corporation $ABUS - Defense World
Will Arbutus Biopharma Corporation stock deliver better than expected guidanceShort Setup & Long Hold Capital Preservation Plans - newser.com
Arbutus Biopharma's CFO David Hastings sells shares worth $72,826 - MSN
Assenagon Asset Management S.A. Makes New $122,000 Investment in Arbutus Biopharma Corporation $ABUS - Defense World
Is Arbutus Biopharma Corporation reversing from oversold territoryJuly 2025 WrapUp & Fast Gain Stock Tips - newser.com
Arbutus Biopharma Corporation Stock Analysis and ForecastEarnings Miss Alerts & Easy Tools to Analyze Your Investment Risk - earlytimes.in
Does Arbutus Biopharma Corporation fit your quant trading modelJuly 2025 PostEarnings & Risk Managed Investment Entry Signals - newser.com
Can machine learning forecast Arbutus Biopharma Corporation recoveryJuly 2025 Momentum & Expert Curated Trade Setup Alerts - newser.com
Building trade automation scripts for Arbutus Biopharma Corporation2025 Price Momentum & Verified Trade Idea Suggestions - newser.com
What MACD signals say about Arbutus Biopharma Corporation2025 Historical Comparison & Stepwise Trade Signal Implementation - newser.com
Analyzing drawdowns of Arbutus Biopharma Corporation with statistical tools2025 Technical Patterns & Expert Approved Momentum Ideas - newser.com
What machine learning models say about Arbutus Biopharma Corporation2025 Key Lessons & AI Based Buy/Sell Signal Reports - newser.com
Arbutus Biopharma Corporation stock volume spike explainedQuarterly Risk Review & High Win Rate Trade Alerts - newser.com
Is Arbutus Biopharma Corporation stock bottoming outLong Setup & Weekly Setup with ROI Potential - newser.com
what machine learning models say about arbutus biopharma corporationJuly 2025 PreEarnings & Risk Controlled Daily Plans - newser.com
Using economic indicators to assess Arbutus Biopharma Corporation potential2025 Market WrapUp & Stepwise Trade Signal Guides - newser.com
Aug Setups: Whats next for Arbutus Biopharma Corporation stockLong Setup & Weekly Breakout Watchlists - خودرو بانک
Goldman Sachs Group Inc. Raises Position in Arbutus Biopharma Corporation $ABUS - MarketBeat
Reversal indicators forming on Arbutus Biopharma Corporation stockQuarterly Growth Report & Fast Entry Momentum Trade Alerts - newser.com
Aug Rallies: Is Arbutus Biopharma Corporation stock a top performer YTD2025 Price Action Summary & Technical Pattern Based Signals - خودرو بانک
RSI Check: Should I set a stop loss on RELYMarket Performance Report & Free Community Consensus Stock Picks - خودرو بانک
Arbutus: IP Drama With High Stakes (NASDAQ:ABUS) - Seeking Alpha
Finanzdaten der Arbutus Biopharma Corp-Aktie (ABUS)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.15%
1.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):